Bringing central laboratory equivalent blood testing to anyone, anywhere

Through its novel automated benchtop platform, Truvian Health ('Truvian') is aiming to create a world where central laboratory equivalent blood tests are available anywhere you go. Truvian has announced an injection of $74 million of capital to be used in part to secure US Food and Drug Administration (FDA) clearance for its blood testing platform.

In the United States, approximately 50% of adults skip routine blood testing because it is overwhelmingly complex and friction-laden with prolonged turnaround times that result in delayed medical intervention or missed diagnoses leading to significant, avoidable costs to the US healthcare system. Truvian's automated benchtop platform hopes to change this by enabling simple, accurate, and comprehensive routine blood tests to be performed in clinics, doctor’s offices and pharmacies.

Over the past twelve months, Truvian has presented data from multiple independent clinical studies demonstrating that results from its platform are equivalent to those produced in a central laboratory across a large panel of tests. It has shared evidence that demonstrates how a multi-modal platform can achieve clinical performance equivalent to the central laboratory across a large panel of tests with a single sample. To date, Truvian’s integrated platform has been evaluated on more than 50,000 samples across 5,000 donors while achieving a platform run reliability rate of greater than 98%. Truvian has also scaled its instrument and consumable manufacturing capabilities to initiate its clinical trials and early partner access programs.

Truvian is attending the ADLM 2024 Clinical Lab Expo (July 30–August 1, Chicago), where it will be offering the company’s benchtop device for FDA approval for people to draw their own blood and get results in minutes. UCSD School of Medicine will also be announcing and sharing findings from an independent study supporting a growing body of evidence that suggests the future of routine blood testing will be defined by automated, benchtop systems that provide decentralized diagnostics anywhere you go. A-323. Advancing Point-of-Care Testing: Independent Evaluation of the Truvian Platform: July 30, from 9:30 to 17:00 central time.

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>